CEL-SCI Corporation (NYSEAMERICAN:CVM) releases details from discussion of results of CEL-SCI’s Phase 3 trial at the Annual Shareholder Meeting on July 1 The discussion on the Phase 3 results was presented by Geert Kersten the Chief Executive Officer, Dr. Eyal Talor the Chief Scientific Officer and John Cipriano the Senior Vice President of Regulatory Affairs. …